anonymous
Guest
anonymous
Guest
Q1: Do the benefits of OCA 25mg outweigh the risks in NASH patients with stage2 or 3 fibrosis?
2 yes, 12 No, 2 abstained.
we’re cooked
2 yes, 12 No, 2 abstained.
we’re cooked
Q1: Do the benefits of OCA 25mg outweigh the risks in NASH patients with stage2 or 3 fibrosis?
2 yes, 12 No, 2 abstained.
we’re cooked
Today I’m thinking of everyone who goes back to the days of RK, or even those who go back to the office in meatpacking. Some great memories from back then, despite all the craziness.
The optimism of early nash was contagious. Don’t think anyone saw this coming back then. But the writing was on the wall since ~2019-20. Unfortunate for the patients. Hope some other treatment options make it to market.
This is not a good drug for treating NASH unless you are into Euthanizing the sick. Hope management sticks a fork in it, it's just not a good idea to keep trying to push it forward.
We heard you Tim. Enough already. We all know what happened today so let it go and let’s move on.
But there’s a bright side hi me. No promotion for you.
LR swore up and down that we'd prove the sell investors wrong.
You can't use brute force, bulldog sales tactics to change the science.
LR swore up and down that we'd prove the sell investors wrong.
You can't use brute force, bulldog sales tactics to get a change the science.
Sooo, what did you expect her to do, tell you to run for the hills and that the sky is falling? No good options, so she tried to keep people motivated.
Frankly, this whole thing was an exercise in futility, but I guess the sunk costs were such that it didn't make sense not to at least try and see it through, but the outcome could never have been in doubt.
LR is an individual who cares about people. She was doing her job. I have nothing but respect for her. If you have issues with her talk to her she is very approachable and if you have a great idea she will listen. #loveuLR
Heres an idea- wait until 303 is completely finished with outcomes before resumbitting, as FDA suggested.
Heres an idea- wait until 303 is completely finished with outcomes before resumbitting, as FDA suggested.
First LR, had nothing to do with filing strategy. Second, management has an obligation to create value for shareholders and there wasn't really much of a downside to filing early, they could still re-file upon completion of 303. Regardless it's all moot, NASH is dead.